Acquired von Willebrand syndrome (AVWS) is reported in high-flow highshear congenital cardiac disorders. We hypothesized that the narrowed pulmonary vasculature in idiopathic pulmonary arterial hypertension (IPAH) may induce AVWS. We conducted a cross-sectional evaluation of children with IPAH. Patients with bleeding symptoms and/or laboratory abnormalities (thrombocytopenia, anomalies in coagulation screening tests) were tested in-depth for haemostatic defects. Fourteen children were followed with IPAH of which 8 were eligible. Four children exhibited abnormal bleeding scores (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool: 3-5). All 8 patients showed very prolonged platelet function analyser (PFA)-100 closure times. Six children demonstrated either mild thrombocytopenia or low-normal von Willebrand factor (VWF) antigen (VWF:Ag) or VWF activity [mean (range), in iu/dl: VWF:Ag: 70 (61-91); VWF activity: 57 (34-70)]. Average VWF collagen binding capacity (VWF:CB) was 64 iu/dl (range: 53-123 iu/dl), with low-normal VWF activity/VWF:Ag or VWF:CB/VWF:Ag ratios occurring in five patients. All children had normal multimers distribution patterns. One patient underwent a lung transplantation, with normalization of haemostatic abnormalities post-surgery. Overall, 8 out of 14 children with IPAH had mild to moderate bleeding symptoms and/or laboratory abnormalities in keeping with AVWS. Normalization of the haemostatic defects following lung transplantation and lack of family history of bleeding attests to the acquired nature of their defects.
congenital heart defects as it is not looked for and additionally usually resolves with correction of the underlying congenital heart defect. Within congenital heart defects, AVWS has been described with ventricular septal defects, aortic stenosis, pulmonary stenosis, coarctation of the aorta and persistent ductus arteriosus (Gill et al, 1986; Rauch et al, 2002; Loeffelbein et al, 2014; Avila et al, 2015; Cochran et al, 2017) . In the setting of congenital or acquired heart defects, AVWS is caused by high-shear lesions that result in uncoiling of the VWF, which then increases its susceptibility to proteolytic cleavage by ADAMTS-13 (Tsai et al, 1994) . The conformational change of VWF is also thought to influence its affinity to glycoprotein Ib (GPIb) and thus, its interactions with platelets. High-shear induced platelet activation, dependent on VWF-GPIb binding, may lead to local activation of coagulation (Miyazaki et al, 1996) .
Pulmonary hypertension is defined as a pulmonary arterial pressure of >25 mmHg at rest and >30 mmHg with exercise and can be idiopathic (primary) or secondary to congenital heart disorders (Donti et al, 2007) . Its pathophysiology is multifactorial and includes inflammation, local thrombosis, vasoconstriction (especially in children) and pulmonary vasculature proliferation. Thus, it is characterized by narrowed pulmonary vasculature. Although the link between pulmonary hypertension and AVWS has not been previously made, abnormal proteolytic degradation of VWF multimers resulting in reduced high molecular weight multimers (HMWM) and a reduced VWF activity/VWF antigen (VWF:Ag) ratio has been described in pulmonary hypertension (Lopes & Maeda, 1995; Veyradier et al, 2000) . Another report has described circulating platelet aggregates, suggesting in vivo platelet aggregation in patients with pulmonary hypertension (Lopes et al, 1993) . These reports suggest that the abnormal flow/shear through the pulmonary vasculature in patients with pulmonary hypertension is having a myriad of impacts on various components of haemostasis.
Our group has recently identified children with idiopathic pulmonary arterial hypertension (IPAH) who have bleeding symptoms and haemostatic profiles analogous to that seen in patients with AVWS in the setting of high-flow high-shear cardiac defects. We theorized that children with IPAH may have an analogous condition to that seen in high-flow highshear cardiac lesions. In IPAH we believe that the entire narrowing of the pulmonary vasculature represents a high-flow high-shear lesion. In this paper we aim to describe the haemostatic defects in children with IPAH.
Methodology

Study design
We conducted a cross-sectional assessment of children followed in our institution with IPAH. As part of scheduled clinic visits, the severity of bleeding symptoms was assessed using a standardized tool, the ISTH-BAT (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool) (Rodeghiero et al, 2010) and baseline screening testing [Complete blood count (CBC), prothrombin time (PT), reported as International Normalized Ratio (INR), activated thromboplastin time (aPTT)] was performed. An ISTH-BAT bleeding score ≥3 was considered abnormal for patients of both genders (Elbatarny et al, 2014) . Patients' charts were also reviewed, and the following data were collected: comorbidities, medications, results of previous cardiology testing (echocardiography, exercise tests, cardiac catheterizations) and treatment-related data (medical therapies for IPAH, haemostatic treatments). Severity of IPAH was estimated by the modified New York Heart Association functional status (NYHA), where class I refers to no limitation to physical activity, class II refers to mild limitation of physical activity, class III refers to marked limitation of physical activity and class IV refers to inability to carry out any physical activity. Patients with bleeding symptoms and/or abnormal screening laboratory tests were referred to the Bleeding Disorders' Clinic for specialized haemostatic testing, including platelet function analyser (PFA)-100, VWF:Ag, VWF activity using ristocetin (VWF:RCo) or GPIbM (VWF:GPIbM)-based assay, VWF collagen binding capacity (VWF:CB), VWF propeptide (VWFpp), VWF multimer analysis, factor VIII activity (FVIII:C) measurement, platelet aggregation and platelet transmission electron microscopy. It was decided a priori that parents of such children would be tested for a bleeding disorder only if they presented with excessive bleeding symptoms or if the family history was suggestive of a bleeding disorder.
This report describes in detail the patients who were: (i) aged 0-18 years old; (ii) diagnosed with IPAH and (iii) referred to the Bleeding Disorders' clinic for one of the following: bleeding symptoms and/or abnormalities identified in screening laboratory tests, including thrombocytopenia (defined in institution as a platelet count <150 9 10 9 / l). Patients were excluded if they had another known bleeding disorder. Despite the association between prostacyclin analogues (PAs), thrombocytopenia and platelet dysfunction (Saniabadi et al, 1984; Belch et al, 1993; Chin et al, 2009 ), we did not exclude children receiving PAs, as this medication is widely used in the treatment of moderate to severe pulmonary hypertension, but recorded their use, as well as start and stop dates in relation to clinical symptoms and laboratory testing. Whenever possible, blood sampling was repeated at least 12 weeks apart. When more than two samples were available for a subject, the latest two were included in this report and in statistical analyses.
Laboratory testing
Analyses were performed as per usual institutional guidelines. Whole blood was collected into 3Á2% sodium citrate tubes, using a 1:9 ratio. Blood specimens were centrifuged at 4200 rpm for 5 min to produce platelet-poor plasma and analysed within 4 h, or frozen at À80°C. PFA-100 closure times were measured using the PFA-100 â (Siemens AG, Munich, Germany) using citrated whole blood. Closure time was determined with the Collagen/epinephrine (Col/Epi) cartridges and, whenever abnormal, with the Collagen/ADP (Col/ADP) cartridges. Upper limits of normal were 168 s (Col/Epi) and 123 s (Col/ ADP) (Carcao et al, 1998) . Light transmission aggregometry using citrate platelet-rich plasma was performed within 4 h of blood collection to determine platelet aggregation. Factor VIII coagulant activity (FVIII:C) was measured using a one-stage assay. VWF:Ag was determined using immunoturbidimetric latex particle assay (Stago Liatest VWFpp levels were determined using ELISA (Sanquin Blood Supply Foundation, Amsterdam, Netherlands). In normal individuals, the VWFpp/VWF:Ag ratio is approximately 1 (range, 0Á9-1Á45) (Sztukowska et al, 2008) . Multimer analysis was performed using gel electrophoresis, as described previously (Stakiw et al, 2008) . For densitometric evaluation, low molecular weight multimers (bands 1-5), intermediate molecular weight multimers (bands 6-10) and high molecular weight multimers (HMWM; >10 bands) were compared.
Ethical considerations
Informed consent was obtained from patients (if ≥16 years of age) or from their parent(s) or legal guardians (if <16 years of age) and assent was obtained for children aged 8 -15 years. The project was approved by the Research Ethics Board of the Hospital for Sick Children, Toronto, Canada.
Statistical analysis
Demographic data and clinical characteristics of the study population were summarized descriptively. Continuous variables were summarized using mean, median, standard deviation, inter-quartile range or range, as appropriate. Categorical variables were summarized using frequencies and percentages.
Results
Demographic and clinical features
Fourteen children are currently followed for IPAH at our institution, of whom 8 (57Á1%) were found to have either bleeding symptoms and/or laboratory haemostatic abnormalities. These 8 patients were then recruited for further investigation and constitute the population for this study. Clinical details on the 8 identified patients are included in Table I . Mean age was 12 years (range: 6-17 years) and female to male distribution was 5:3. All patients were receiving between 1 and 3 medications directed at pulmonary hypertension at the time of referral. These included diuretics (furosemide, n = 1), endothelin-receptor antagonists (bosentan, n = 1; macitentan, n = 3), type 5 phosphodiesterase inhibitors (sildenafil, n = 4) and PAs (trepostinil, n = 3; epoprostenol, n = 2; selexipag, n = 1). One patient had been receiving aspirin (as an anti-platelet agent), which was stopped because of recurrent epistaxis, and one had received warfarin as thromboprophylaxis in the setting of decreased cardiac function.
Four of the eight patients had abnormal ISTH-BAT scores (defined as ≥3) while the mean ISTH-BAT score for all eight patients was 2Á9 (range: 0-5) ( Table I ). The most common bleeding symptoms were epistaxis (n = 6) followed by menorrhagia (n = 2). Five patients required supportive treatment for their bleeding symptoms, including local interventions for epistaxis (n = 4), hormonal therapy (n = 1) for heavy menstrual bleeding and iron supplementation (n = 1) due to development of iron deficiency anaemia secondary to bleeding. In all cases, there was no family history suggestive of an inherited bleeding disorder.
Laboratory features
Main laboratory findings are shown in Table II . For five children, a second blood sample was taken at their follow-up visit, 3 to 6 months after the initial blood sample. Haemoglobin values were within normal range for all patients [mean (range) = 135 g/l (123-157 g/l)]. Six patients exhibited mild thrombocytopenia (platelet counts between 101 and 149 9 10 9 /l); the mean platelet count for all eight patients was 158 9 10 9 /l. INR and PTT were normal for all patients. All patients showed extremely prolonged PFA-100 closure times. Most patients demonstrated VWF:Ag and VWF activity levels towards the lower limit of normal range and low-normal VWF activity/VWF:Ag ratios. Mean values (range) for VWF:Ag and VWF activity were 70 iu/dl (61-91 iu/dl) and 57 iu/dl (34-70 iu/dl), respectively. VWF:CB was also towards the lower limit of normal range for most patients, on average 64 iu/dl (range: 53-123 iu/dl). VWFpp/ VWF:Ag was normal in five patients, marginally elevated in two patients and very elevated in one patient, indicating . Platelet aggregation and platelet transmission electron microscopy were within normal limits for all patients. Multimer testing showed normal distribution of multimers in all patients (see Fig 1) , with HMWM (>10 bands) constituting anywhere from 5Á9% to 15Á9% (normal control: 7Á7%) of the total multimers.
Comparison with unaffected patients
Six of the 14 patients in the institution with IPAH had no excessive bleeding symptoms and normal platelet counts [median platelet count: 201 9 10 9 /l (range: 152-259 9 10 9 /l)].
The median pulmonary artery pressure of these six patients was 48 mmHg (range: 21-87 mmHg). These unaffected patients had a median age of 11Á5 years (range: 7Á0-14Á0 years) and the female to male ratio was 2:1. Three of these six patients were receiving PAs. VWF:Ag was measured in three of these patients and was within normal limits (mean 79 iu/dl, range: 61-92 iu/dl). VWF activity, VWF:CB, multimer testing and PFA-100 CT were not available in unaffected patients.
Effects of correction of pulmonary hypertension
One patient (Patient 8 in Tables I and II ) underwent a double-lung transplant for worsening pulmonary hypertension. She received a VWF:FVIII concentrate (Humate-P, CSL Behring, King of Prussia, PA, USA) at a dose of 65 ristocetin co-factor (RCoF) u/kg pre-operatively; a repeat dose of 25 RCoF u/kg was given 9 h later perioperatively, as she experienced bleeding at the surgical site requiring red cell and platelet transfusions. She did not receive additional doses of VWF:FVIII concentrates post-surgery, and all pulmonary hypertension-targeted medications were stopped post-surgery. We observed supra-normalization of her coagulation abnormalities post-operatively (see Table III ).
Discussion
We report a cross-sectional assessment of 14 children with IPAH. Eight (57Á0%) of these 14 children exhibited mild to moderate bleeding symptoms, mild thrombocytopenia, markedly prolonged PFA-100 closure times (much more than expected for their platelet counts, haemoglobin values or VWF levels) and VWF:Ag and VWF activity levels that were either low or in the lower range of normal, all of which are in keeping with AVWS. VWFpp/VWF:Ag ratio was elevated in 3 out of 7 patients. Interestingly, multimer analysis showed normal to arguably supra-normal HMWM at baseline. Typically, HMWM are thought to be reduced in AVWS in the setting of high-shear lesions. However, the situation in pulmonary hypertension may be different. Other authors have also similarly found conflicting results with multimer analysis in pulmonary hypertension. Collados et al (1999) studied the multimer profiles of adults with primary pulmonary hypertension: while a decrease in HMWM was noted in patients responding to vasodilators, non-responders to vasodilators had an increase in HMWM, and even ultralarge VWF multimers. The authors speculated that, as in other diseases characterized by endothelial dysfunction, increased secretion of VWF might overwhelm the natural proteolysis of VWF. Of note, chronic endothelial activation has also been linked to increased secretion of VWFpp and marginally increased VWFpp concentration (van Mourik et al, 1999) ; elevated VWFpp has been used as a biomarker of endothelial activation in several diseases including chronic renal failure, aortic stenosis, and sickle cell disease (Haberichter, 2015) . The underlying mechanism for AVWS in IPAH is not fully elucidated. Pulmonary hypertension is characterized by narrowed pulmonary arterial vasculature. We suspect it may cause a high-flow high-shear physiological state which leads to uncoiling of VWF multimers and its subsequent proteolytic cleavage by ADAMTS-13 along with in vivo activation of platelets. It is also possible that endothelial cell injury somehow alters the synthesis, secretion or clearance of VWFpp and mature VWF.
The absence of a family history of bleeding in all cases and the complete correction of the haemostatic defects following a double lung transplantation in 1 patient point to the acquired nature of these defects. Furthermore, congenital von Willebrand disease (VWD) (other than type 2b) would not be expected to cause thrombocytopenia in these patients; note that type 2b VWD would have shown enhanced ristocetin-induced platelet agglutination, which was not seen on platelet aggregation testing. However, PAs, such as Epoprostenol, Treprostinil or Selexipag, given as continuous subcutaneous infusions in six of our patients could be potential confounders as a cause of bleeding symptoms, given that PAs interfere with platelet aggregation. Nonetheless, two patients (Patients 4 and 6) didn't receive PAs and yet had similar laboratory findings while two other patients were exhibiting bleeding symptoms even before PAs had been initiated. Conversely, three of the six patients with pulmonary hypertension but without bleeding symptoms or thrombocytopenia (and as such not referred for further investigation) were on PAs. Moreover, PAs could theoretically affect PFA-100 and platelet function tests but would not be expected to cause reduced VWF:Ag or VWF activity levels and therefore would not explain our findings. Lastly, platelet aggregation testing was normal in all patients thus indicating an absence of an inherited or acquired platelet function disorder. Therefore, we suspect that the observed haemostatic defects are not explained by use of PAs and are not inherited but instead are an acquired phenomenon (AVWS) secondary to the underlying pulmonary hypertension.
Very little is known about the association of AVWS and IPAH. The first report suggesting a possible association was that of an adolescent female with IPAH who concomitantly experienced menorrhagia (Sokkary et al, 2011) . A recent report by Hashmi et al (2017) described 16 paediatric patients with AVWS in the setting of various cardiopulmonary disorders (CPD); four of the 16 patients had pulmonary hypertension secondary to underlying CPD but one did have IPAH. Four of the five patients with pulmonary hypertension reported bleeding symptoms and were found to have reduced VWF activity/VWF:Ag ratios. Our results suggest that AVWS may be a common phenomenon amongst children with IPAH.
Among children with IPAH, there was no clear differences among children with and without AVWS in terms of age, sex, medication profile and mean pulmonary artery pressure, but our study had a small sample size and was not designed to compare both groups of children. Further research will be needed to identify what factors contribute to development of AVWS in some children with IPAH but not others.
The clinical significance of AVWS remains controversial. Some authors have observed very low rates of bleeding in patients with AVWS secondary to CPD (Casonato et al, 2011; Loeffelbein et al, 2014) . Conversely, some authors have reported increased rates of post-operative and intracranial bleeding in the setting of congenital heart disease and/or use of ventricular assist devices (Onimoe et al, 2011; Jones et al, 2016) . In our cohort, most patients exhibited only mild bleeding symptoms; the one patient that underwent a doublelung transplantation did sustain peri-operative haemorrhage despite having received a VWF concentrate. The type of bleeding exhibited by patients in our cohort mimics other reports of AVWS (Federici et al, 2000; Tiede et al, 2008) , with the exception that we did not observe gastro-intestinal bleedingusually a complication of angiodysplasia. This might be attributable to the young age of our cohort, as gastro-intestinal bleeding is more commonly seen in adults, rather than in children with both congenital and acquired VWD (Crow et al, 2010) . In our cohort, there was no clear correlation between the severity of IPAH and the severity of the bleeding symptoms and/or the laboratory abnormalities, but our small sample size precludes firm conclusions. This study highlights the difficulties of making a definitive diagnosis of AVWS. There are currently no standardized diagnostic criteria, as some authors have used loss of HMWM, reduced VWF:RCo or VWF:CB levels, reduced VWF activity/VWF:Ag ratios or a combination of criteria (Federici et al, 2000; Tiede, 2012; Baghai et al, 2015; Heilmann et al, 2017) . Tiede et al (2008) reported a sensitivity of 50% in adults with cardiovascular disease and presumed AVWS when using a combination of tests (a reduction of any of the following: VWF:RCo, VWF:CB, VWF:RCo/VWF: Ag ratio or VWF:CB/VWF:Ag ratio). The authors concluded that sensitivity could be increased by using a VWF:CB/VWF: Ag ratio cut-off of <0Á8. As discussed above, multimer analysis might not be as reliable as a diagnostic tool in pulmonary hypertension. In our cohort, in the absence of a diagnostic gold standard, diagnosis was based on a constellation of findings, given the heterogeneity of clinical and laboratory features exhibited by our patients. Strikingly, the PFA-100 closure times were markedly elevated in all patients, which may reflect a global haemostatic defect. The sensitivity of PFA-100 testing in AVWS has been shown to be 80% in adults (Tiede et al, 2008) , but to our knowledge there are no similar data in children. Diagnostic criteria are needed to help clinicians diagnose paediatric AVWS.
Our study must be interpreted in light of its limitations. First, our cross-sectional design did not allow the capture of how the clinical and laboratory manifestations of AVWS in children with IPAH may fluctuate with treatment and over time with progression of pulmonary hypertension. Also, as mentioned above, PAs were used by 5 children and could not be interrupted for laboratory testing, given their clinical importance. Thirdly, the effect of corrective surgery (lung transplantation) could be assessed in only one patient, as lung transplantation is rarely undertaken now in the paediatric population, given recent therapeutic advances (Donti et al, 2007) . Further follow-up will be necessary to assess if the normalization of laboratory abnormalities can be replicated in other patients undergoing double-lung transplantation for correction of IPAH. Lastly, first-degree relatives of children have not been tested to formally exclude inherited VWD. Despite the above, we believe that given the absence of any family history of bleeding and the constellation of laboratory defects observed (thrombocytopenia, low-normal VWF:Ag, VWF activity and VWF:CB, along with significant prolongation of PFA) that a diagnosis of inherited VWD would not fit these children and, most telling, it would not have resolved following lung transplantation.
In summary, we describe eight children with IPAH and clinical and laboratory features suggestive of AVWS, possibly caused by increased shear stress throughout the pulmonary vasculature. The correction of abnormalities following correction of the IPAH attests to the acquired nature of this disorder. Larger prospective studies will be required to further characterize the incidence and natural history of this condition.
